Login to Your Account

SHANGHAI – U.S.-China biotech CASI Pharmaceuticals Inc. initiated dosing in Chinese patients with ENMD-2076, a selective angiogenic kinase inhibitor, in a phase II study for triple-negative breast cancer (TNBC).
HONG KONG – Calling success in the first proof-of-concept trial for its cancer drug, fruquintinib, Hong Kong-based Hutchison Medipharma said the drug achieved primary efficacy endpoints.

Shares in Innate Pharma SA fell 14 percent Thursday on news that a DSMB called a halt to one treatment arm of a phase II trial in AML testing lirilumab (IPH2102, BMS-986015), an immunotherapeutic antibody that targets inhibitory KIRs expressed by NK cells.

More IN THE CLINIC Headlines

Cast Your Vote

Has biotech’s bubble burst?: